Transdel Pharmaceuticals Close to Signing Lucrative Pharma Partnership Deals
31 December 2010LOS ANGELES, CA, Jul 27, 2010 (MARKETWIRE via COMTEX) -- According to a newly published report, Transdel Pharmaceuticals' /quotes/comstock/11k!tdlp (TDLP 1.20, 0.00, 0.00%) proprietary transdermal cream drug delivery platform is an asset that pharmaceutical companies have taken notice of and the company may be on the verge of announcing some significant news.
Transdel has developed their topical anti-inflammatory cream, called Ketotransdel(R), for the treatment of acute pain.
"Basically our technology utilizes a combination of penetrator enhancers to take the drug through the skin barrier and delivering it to the affected tissues," explains John Lomoro, CEO and CFO of Transdel.
What makes the company so interesting to investors right now are the rumors that Transdel is very close to a deal with one or two companies and that could mean a $10 million upfront cash deal as well as the expenses for an additional FDA trial being paid for by those partners.
BioMedReports today is reporting that the company could receive royalty payments in excess of 25%.
"Yes, we will partner this product," explains Lomoro. "When I signed on with the company I was given a mandate by the board that we wanted to be a fully integrated specialty pharma company and to accomplish that the goal we need to partner out the Ketoprofen program, either on a global basis or on regional deals, and we have pursued those partnerships aggressively.
"We are in late stage discussions with potential regional partners and with a global partner. The idea being that we would set it up where we would sit back a clip coupons and have a joint development committee where they would participate in the development and exercise of the Phase 3 studies and registration process, meaning they would pay for it."
Investors can read the complete report complete with more comments from John Lamoro today at BioMedReports.Com:
http://biomedreports.com/articles/most-popular/48598-transdermal-drug-delivery-platform-on-the-verge-of-something-big.html
In addition, Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:
http://biomedreports.com/fda-calendar/fda-calendar.html
About BioMedReports.Com BioMedReports.com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies.
For more biomedical sector and investment news go to http://BioMedReports.com
SOURCE: BioMedReports
. Want more information about prescription glasses?